Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 07, 2019

SELL
$22.8 - $33.93 $11,742 - $17,473
-515 Closed
0 $0
Q3 2018

Oct 12, 2018

BUY
$29.75 - $43.08 $15,321 - $22,186
515 New
515 $19,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $212M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Dorsey Wright & Associates Portfolio

Follow Dorsey Wright & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Dorsey Wright & Associates with notifications on news.